Alpa Laboratories Limited — Important, 14-11-2024: Financial Result Updates

**Alpa Laboratories Ltd. Financial Summary**

Consolidated results show a total revenue from operations of ₹3,184.89 crore, reflecting a year-over-year growth of approximately 10%. This growth can be attributed to increased market demand and strategic operational improvements. Other income contributed an additional ₹690.96 crore, bringing total income to ₹3,875.85 crore.

Net profit for the quarter stands at ₹768.64 crore, an improvement from ₹578.99 crore in the same period last year, resulting in an Earnings Per Share (EPS) of ₹3.66. Profitability has been supported by better cost control measures, especially in employee benefits and operational expenses.

Total expenses increased to ₹2,312.76 crore from ₹2,260.76 crore, indicating a rise of about 2.3%. Notably, costs associated with materials increased, in line with enhanced production volumes. However, the company's focus on cost efficiency and operational scalability is evident from its ability to maintain profit margins amid rising costs.

In terms of the balance sheet, total assets increased to ₹2,095.17 crore, with equity share capital remaining stable at ₹2,104.06 crore. The current ratio is healthy, indicating strong liquidity.

Strategically, the company seems poised for continued growth, with emphasis on market expansion and innovation.

Given the solid financial performance, effective cost management, and favorable outlook, a **buy** perspective appears justified for retail investors.